These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17965515)

  • 1. Microdosing for reduction of the time and resources for drug development.
    Sudo K
    Drug Metab Pharmacokinet; 2007 Oct; 22(5):327. PubMed ID: 17965515
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of drug metabolites.
    Izumi T
    Drug Metab Pharmacokinet; 2011; 26(2):121-2. PubMed ID: 21532211
    [No Abstract]   [Full Text] [Related]  

  • 3. Consider drug efficacy before first-in-human trials.
    Kimmelman J; Federico C
    Nature; 2017 Jan; 542(7639):25-27. PubMed ID: 28150789
    [No Abstract]   [Full Text] [Related]  

  • 4. A model-based assay design to reproduce in vivo patterns of acute drug-induced toxicity.
    Kuepfer L; Clayton O; Thiel C; Cordes H; Nudischer R; Blank LM; Baier V; Heymans S; Caiment F; Roth A; Fluri DA; Kelm JM; Castell J; Selevsek N; Schlapbach R; Keun H; Hynes J; Sarkans U; Gmuender H; Herwig R; Niederer S; Schuchhardt J; Segall M; Kleinjans J
    Arch Toxicol; 2018 Jan; 92(1):553-555. PubMed ID: 28852801
    [No Abstract]   [Full Text] [Related]  

  • 5. De-risking drug discovery with ADDME -- avoiding drug development mistakes early.
    Tsaioun K; Jacewicz M
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():47-55. PubMed ID: 19807206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current drug metabolism.
    Kerns EH
    Curr Drug Metab; 2008 Nov; 9(9):845-6. PubMed ID: 18991579
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetics and toxicokinetics of bio-pharmaceuticals: technical problems.
    Kawai M
    J Toxicol Sci; 1996 Dec; 21(5):535-7. PubMed ID: 9035067
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
    Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
    Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs in control samples in nonclinical safety studies: a reconsideration.
    Zimmer D
    Bioanalysis; 2016 May; 8(10):1003-7. PubMed ID: 27080047
    [No Abstract]   [Full Text] [Related]  

  • 10. High throughput ADME screening: practical considerations, impact on the portfolio and enabler of in silico ADME models.
    Hop CE; Cole MJ; Davidson RE; Duignan DB; Federico J; Janiszewski JS; Jenkins K; Krueger S; Lebowitz R; Liston TE; Mitchell W; Snyder M; Steyn SJ; Soglia JR; Taylor C; Troutman MD; Umland J; West M; Whalen KM; Zelesky V; Zhao SX
    Curr Drug Metab; 2008 Nov; 9(9):847-53. PubMed ID: 18991580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug metabolites in safety testing.
    Hastings KL; El-Hage J; Jacobs A; Leighton J; Morse D; Osterberg RE
    Toxicol Appl Pharmacol; 2003 Jul; 190(1):91-2;author reply 93-4. PubMed ID: 12831788
    [No Abstract]   [Full Text] [Related]  

  • 12. Predicting human pharmacokinetics from preclinical data.
    Poggesi I
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):100-11. PubMed ID: 14982153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microdosing Studies in Children: A US Regulatory Perspective.
    Roth-Cline M; Nelson RM
    Clin Pharmacol Ther; 2015 Sep; 98(3):232-3. PubMed ID: 26095312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
    Yan Z; Caldwell GW
    Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A "White Knight" role for DMPK researchers in pharmaceutical discovery: maximization of biomarker and translational M&S activities.
    Teramura T
    Drug Metab Pharmacokinet; 2012; 27(4):365-7. PubMed ID: 23268314
    [No Abstract]   [Full Text] [Related]  

  • 16. Theory and practice of prodrug kinetics.
    Notari RE
    Methods Enzymol; 1985; 112():309-23. PubMed ID: 4046852
    [No Abstract]   [Full Text] [Related]  

  • 17. In silico methods to predict drug toxicity.
    Roncaglioni A; Toropov AA; Toropova AP; Benfenati E
    Curr Opin Pharmacol; 2013 Oct; 13(5):802-6. PubMed ID: 23797035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging technologies for the study of drug metabolism and pharmacokinetics.
    Hsieh Y
    Curr Drug Discov Technol; 2010 Sep; 7(3):141-2. PubMed ID: 20843297
    [No Abstract]   [Full Text] [Related]  

  • 20. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.
    Caldwell GW; Ritchie DM; Masucci JA; Hageman W; Yan Z
    Curr Top Med Chem; 2001 Nov; 1(5):353-66. PubMed ID: 11899102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.